Prihlásiť sa Zaregistrujte sa zadarmo

Pomer krátenia spoločnosti Edesa Biotech

Aká je hodnota metriky Pomer krátenia spoločnosti Edesa Biotech?

Hodnota metriky Pomer krátenia spoločnosti Edesa Biotech, Inc. je 5.73

Aká je definícia metriky Pomer krátenia?



Pomer krátenia (Short ratio) je pomer akcií predaných na krátko a priemerným denným objemom.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

Pomer krátenia spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Edesa Biotech

Čomu sa venuje spoločnosť Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Firmy s metrikou pomer krátenia podobnou spoločnosti Edesa Biotech